Ainos

AIMD

市值 US$682萬

Partner's Written Confirmation Fulfills Payment Conditions; Initial License Fee Payable Within 15 Business Days HOUSTON, TX / ACCESS Newswire / September 30, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has completed the required data delivery and technology transfer under its VELDONA® license agreement, triggering a $600,000 initial license payment. The licensing partner confirmed completion in writing on September 29.

Preparations underway for a larger-scale second-phase deployment specified in the existing MOU, building on first-phase deployment experience Advanced packaging deployment marks a major step for Ainos' Chemical Intelligence platform, alongside commercial progress in advanced wafer fabrication HOUSTON, TX / ACCESS Newswire / September 29, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has completed delivery of all 1,400 AI Nose systems to ASE Technology Holding Co., Ltd. ("ASE") under the announced $2.1 million, three-year agreement.

Initial license payment tied to near-term contractual delivery; additional payment opportunities may arise during development, before drug approval Partner assumes assigned clinical and regulatory funding and execution, reducing Ainos' independent capital and staffing requirements Ainos retains existing platform ownership and 25% of applicable net sublicensing revenue; potential economic participation extends beyond the $10 million licensing framework HOUSTON, TX / ACCESS Newswire / September 28, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today detailed the financial and strategic benefits of the VELDONA® License Agreement announced on September 24, 2026 (the "Agreement"). Ainos expects to complete the agreed contractual delivery shortly, with an initial license fee of $600,000 payable within 15 business days after the applicable payment conditions are satisfied.

Partner-funded development marks an important milestone for VELDONA, with BioPhoenix funding and advancing clinical and regulatory development for two initial indications Development funding is additional to the framework; Ainos retains core platform ownership, product supply opportunities and contractual participation in downstream commercial revenue HOUSTON, TX / ACCESS Newswire / September 24, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has entered into a VELDONA® License Agreement with BioPhoenix Co., Ltd. ("BioPhoenix"), establishing a collaboration framework with a potential aggregate value of $10 million.

Report points to front-end semiconductor orders, a $2.1 million back-end program and continued dataset expansion as key indicators of Ainos' growing commercial scale HOUSTON, TX / ACCESS Newswire / September 16, 2026 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company") today highlighted a new research update from VASRO GmbH that points to strengthening commercial momentum for Ainos' AI Nose platform across semiconductor applications, supported by initial front-end orders, an established back-end subscription program and a proprietary real-world chemical dataset that has surpassed 1 billion records. VASRO highlighted two developments that it views as important markers in Ainos' semiconductor commercialization: the transition of its front-end semiconductor program from validation to initial commercial orders, and the expansion of its proprietary real-world chemical dataset beyond 1 billion records.

Initial commercial orders mark progress toward broader commercial adoption and support revenue-generation opportunities beginning in 2H 2026 Proprietary real-world chemical dataset surpasses 1 billion records, strengthening Ainos' Chemical Intelligence foundation HOUSTON, TX / ACCESS Newswire / September 14, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that its second-generation AI Nose platform is advancing into commercial deployment in front-end semiconductor manufacturing, building on validation activities initiated earlier this year involving approximately 200 AI Nose systems. Ainos is receiving initial commercial orders from a front-end semiconductor company.

New patents cover electronic nose integration with robotics, expanding Ainos' portfolio of 124 patent assets worldwide across chips, sensing architectures, chemical molecules and real-world applications HOUSTON, TX / ACCESS Newswire / September 9, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has secured three new Japanese patents covering AI Nose technologies and their integration with robotic systems. The newly granted patents cover gas exchange, rapid chemical detection and electronic nose integration with robots: Electronic nose with gas exchange system and robot equipped with electronic nose Electronic nose and robot capable of rapid detection Electronic nose for rapid detection and robot equipped with electronic nose The patents expand Ainos' intellectual property portfolio as artificial intelligence increasingly moves beyond digital environments and into the physical world through robots, autonomous machines and other Physical AI systems.

High-efficiency, on-site nitrogen generation is designed to protect high-value AI infrastructure, reduce oxidation and environmental degradation, and bring greater flexibility and resilience to semiconductor manufacturing HOUSTON, TX / ACCESS Newswire / August 19, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced the global launch of Atmosphere Engine™ , a new platform that extends the Company's capabilities in AI-powered environmental sensing, Chemical Intelligence and smart manufacturing into active environmental management. Atmosphere Engine is designed to generate high-purity nitrogen and oxygen directly from ambient air, on-site and closer to the point of use.

Second-generation platform combines upgraded software, firmware, Edge AI and industrial-grade hardware to support reliable 24/7 real-world deployment More than 878 million real-world smell data records strengthen Ainos' Smell Intelligence foundation, with every AI Nose serving as a continuously learning node toward a broader Chemical Intelligence network HOUSTON, TX / ACCESS Newswire / August 17, 2026 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered Chemical Intelligence, today announced the next generation of its AI Nose platform, featuring comprehensive upgrades across software, firmware, edge computing and hardware reliability. The second-generation AI Nose is engineered for continuous, real-world deployment and represents an important step in Ainos' evolution from standalone smell sensing toward a distributed Chemical Intelligence infrastructure for Physical AI.

Dataset expands by approximately 265 million data points since July 21 as continued AI Nose system deployment across semiconductor manufacturing environments accelerates Ainos' Real-World Data Flywheel and Chemical Intelligence development HOUSTON, TX / ACCESS Newswire / August 13, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that its AI Nose platform has surpassed 878 million real-world smell and chemical data points, primarily generated from semiconductor manufacturing and real-world operating environments, marking another significant milestone in the Company's development of Chemical Intelligence for Physical AI. Since reporting approximately 613 million data points on July 21, 2026, Ainos' dataset has expanded to approximately 878 million data points, adding approximately 265 million data points in just 23 days, an increase of approximately 43%.